|Bid||3.7200 x 0|
|Ask||3.7600 x 0|
|Day's Range||3.5800 - 3.9800|
|52 Week Range||2.8700 - 12.8800|
|Beta (5Y Monthly)||3.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 12, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.63|
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the company has received EU-GMP certification for its state-of-the-art medical cannabis production facility in Germany. As a leading manufacturer of medical cannabis worldwide, achieving EU-GMP certification of the company's first German manufacturing site marks a significant milestone in the fulfillment of an awarded tender by the German
No matter your level of experience investing money on Wall Street, it's been a rough year. Meanwhile, the technology-driven Nasdaq Composite declined close to 30% from its November all-time high, firmly placing it in a bear market. This is why Wall Street analysts typically have a bullish outlook on many of the companies they cover.
Canadian cannabis company Aurora Cannabis (NASDAQ: ACB) reported its fiscal third-quarter 2022 earnings last night, and in so doing, sparked a rally across the cannabis sector today. As of 1 p.m. ET, shares of Aurora Cannabis itself are already up 13%, and peer producers Canopy Growth (NASDAQ: CGC) and Sundial Growers (NASDAQ: SNDL) are benefiting as well -- up 8.5% and 5.9%, respectively. Heading into Q3, analysts had forecast that Aurora Cannabis would lose $0.19 per share (0.25 Canadian dollars, and furthermore, this was a pro forma prediction) on sales of $41.5 million -- about CA$53.7 million.